

# Brain Tumor Center Update



## Current Clinical Trials for Adults with Brain Tumor

Questions about patients' participation in the following clinical trials can be directed to Jane Rabbitt or Margaretta Page by calling 415-353-2966, or by email to Mary Malec at [malecm@neurosurg.ucsf.edu](mailto:malecm@neurosurg.ucsf.edu).

For further details about clinical trials for adults being performed through the North American Brain Tumor Consortium (NABTC), visit: <http://www.nabtc.org/>

### Newly Diagnosed Glioblastoma Multiforme

A Phase I Study of Gross Total Resection, Permanent Iodine-125 Brachytherapy, and Hyperfractionated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme

Phase II Study of PolyICLC plus Radiation for Newly Diagnosed Patients with Glioblastoma Multiforme (NABTC 01-05)

Phase I Study of R115777 plus Radiation for Newly Diagnosed Patients with Glioblastoma Multiforme (NABTC 02-02)

### Newly Diagnosed Anaplastic Astrocytoma

A Phase I/III Randomized Study of Radiation Therapy and Temozolomide vs. Radiation Therapy and BCNU vs. Radiation Therapy and Temozolomide and BCNU for Anaplastic Astrocytoma (RTOG 9813)

### Newly Diagnosed Low-Grade Glioma

A Phase I Study of Temozolomide (SCH 52365) in the Treatment of Adult Patients with Supratentorial Low Grade Glioma

### Recurrent Tumor

Phase I/II Trial of R115777 in Patients with Recurrent Malignant Glioma (NABTC 99-01)

Phase I/II Trial of CPT-11 and Temozolomide (Temodar) in Patients with Recurrent Malignant Glioma (NABTC 99-07)

Phase I/II Trial of STI571 in Patients with Recurrent Malignant Glioma (NABTC 99-08)

Phase I/II Study to Assess the Histologic Effect and Safety of Pre-Operative and Post Operative Infusions of IL13-PE38QQR Cytotoxin in Patients with Recurrent Resectable Supratentorial Malignant Glioma

Phase I/II Trial of CCI-779 in Patients with Malignant Glioma (NABTC 01-01)

A Phase I Study of OSI-774 and Temozolomide for the Treatment of Gliomas

ZD 1893 for Treatment of Recurrent or Progressive Malignant Astrocytoma or Glioblastoma and Recurrent or Progressive Meningioma: A Phase II Study with a Phase I Component for Patients Receiving EIAEDs (NABTC 00-01)

A Phase I Study of ZD 1839 and Temozolomide for the Treatment of Gliomas (NABTC 01-02)

A Phase I/II Trial of OSI-774 in Patients with Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy (NABTC 01-03)

A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumor Patients


### Non-Chemotherapy Protocols

Assessment of Needs for Complementary Medicine Program for Patients with Brain Tumors

Study of Distant Healing as an Adjunctive Intervention in Glioblastoma


San Francisco Bay Area Adult Glioma Prognosis Study

A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas (NABTC 01-07)





## Current Clinical Trials For Children With Brain Tumor



UCSF Cancer Center • UCSF Brain Tumor Program  
Department of Neurological Surgery & Brain Tumor Research Center

Questions about patients' participation in the following clinical trials can be directed to Jane Rabbitt or Margaretta Page by calling 415-353-2966, or by email to Mary Malec at [malecm@neurosurg.ucsf.edu](mailto:malecm@neurosurg.ucsf.edu).

For further details about clinical trials for children being performed through the Pediatric Brain Tumor Consortium (PBTC), visit: <http://www.pbtc.org/>

**Pilot Study of Systemic and Intrathecal Chemotherapy Followed by Conformal Radiation for Infants with Embryonal Intracranial Central Nervous System Tumors (PBTC 001)**

This is a risk adapted, multi-modality trial for patients under the age of 3 years newly diagnosed with medulloblastoma/PNET, metastatic ependymoma, or other primary intracranial embryonal tumors. For further details: [http://www.pbtc.org/public/PBTC001\\_HP\\_abstract.htm](http://www.pbtc.org/public/PBTC001_HP_abstract.htm).

**Phase I Trial of Escalating Oral Doses of SCH 66336 in Pediatric Patients with Refractory or Recurrent Brain Tumors (PBTC 003)**

This is a phase I trial for patients 21 years of age or younger, with recurrent or progressive brain tumors. For further details: [http://www.pbtc.org/public/PBTC003\\_HP\\_abstract.htm](http://www.pbtc.org/public/PBTC003_HP_abstract.htm).

**Phase I/II Trial of STI571 in Children with Newly Diagnosed Poor Prognosis Brainstem Glioma and Recurrent Intracranial Malignant Glioma (PBTC 006)**

During the dose-finding component of the trial, children with newly diagnosed, localized, poor-prognosis brainstem gliomas and recurrent intracranial malignant gliomas, including recurrent brainstem gliomas will be studied. For further details: [http://www.pbtc.org/public/PBTC006\\_HP\\_abstract.htm](http://www.pbtc.org/public/PBTC006_HP_abstract.htm).



**A Phase I/II Trial of ZD1839 (Iressa™) and Radiation in Pediatric Patients Newly Diagnosed with Brainstem Tumors or Incompletely Resected Supratentorial Malignant Gliomas with Phase II Limited to Brainstem Tumors (PBTC 007)**

Children with newly diagnosed intrinsic brainstem gliomas (BSG) and incompletely resected supratentorial malignant gliomas (STMG) with residual tumor on imaging will be eligible for this study. For further details: [http://www.pbtc.org/public/PBTC007\\_HP\\_abstract.htm](http://www.pbtc.org/public/PBTC007_HP_abstract.htm).

**Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients with Recurrent Brain Tumors (PBTC005)**

This is a phase I trial for patients 21 years of age or less, with recurrent or progressive brain tumors. For further details: [http://www.pbtc.org/public/PBTC005\\_HP\\_abstract.htm](http://www.pbtc.org/public/PBTC005_HP_abstract.htm).

**Phase I Trial of Gliadel and O6-Benzylguanine in Pediatric Patients with Recurrent Malignant Gliomas (PBTC 009)**

This is a phase I trial for patients from age 3 to 21. For further details: [http://www.pbtc.org/public/PBTC009\\_HP\\_abstract.htm](http://www.pbtc.org/public/PBTC009_HP_abstract.htm).

**A Phase II Study of Oxaliplatin in Children with Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors after Failure of Initial Therapy (PBTC 010)**

This is an open-label, single-agent phase II study of oxaliplatin in pediatric patients with recurrent or refractory embryonal CNS tumors. For further details: [http://www.pbtc.org/public/PBTC010\\_HP\\_abstract.htm](http://www.pbtc.org/public/PBTC010_HP_abstract.htm).

For further details about clinical trials for children being performed at UCSF, visit: [http://www.cc.ucsf.edu/trials/peds\\_brain\\_toc.html](http://www.cc.ucsf.edu/trials/peds_brain_toc.html).

**Brain Tumor Therapy at UCSF** is a collaboration of UCSF's Neurological Surgery, Neuro-Oncology, Radiation Oncology, Gamma Knife®, and Pediatric Programs, with the support of researchers in UCSF's Brain Tumor Research Center (BTRC) and Michael Douglas Pediatric BTRC, and with close ties to organizations sponsoring support groups and other resources for patients with brain tumors.